Psoriasis is a common chronic, immune-mediated, skin disease with a significantly negative impact on patients' quality of life. It is one of papulosquamous diseases defined by erythematous plaques with silvery scales.
The interplay among cytokines released by dendritic, Th1, Th2, and Th17 cells leads to the clinical manifestations seen in psoriasis. Although discovering novel biomarkers for psoriasis is challenging step., it may play an essential role in diagnosis, severity assessment and prediction of treatment outcome and prognosis of the disease
Patients with moderate to severe plaque psoriasis.
No restriction of age, race nor occupation.
History of psoriasis treatment with systemic and biological agents prior to the study for at least 3 months.
Pregnancy and lactation.
Infections.
Patients with chronic diseases: hepatic disorders, hematologic diseases, chronic renal failure or cancer.
Parallel
NB-UVB
Procedure/SurgeryComparison between serum Level of Gelsolin (GSN) in Psoriatic Patients and controls and correlate its level with PASI.
Treatment of the Psoriasis
About 36 patients suffering from Psoriasis and will be treated by exposing to Narrow band ultraviolet B radiation (initial dose of 130 - 400 mJ / cm2 selected according to skin phototype and gradual increase after each session ), and taking Methotrexate tablets in dose of (0.3 mg/kg/week) along with folic acid (5 mg/day) .
Serum Gelsolin Evaluation
Evaluation the Serum Gelsolin level in Psoriatic Patients after treatment by Narrow band ultraviolet B and taking Methotrexate tablets.
Click on the lead sponsor to view all of their trials.
